Find in Library

<p>The clinical data of 100 patients with acute ischemic stroke on admission and 30 d after stroke were analyzed. The patients were evenly divided into 2 groups (statin group and control group). Serum high-sensitivity C-reactive protein (hs-CRP) level was similar in the 2 groups within 48 h after onset, but was significantly lower in statin group 30 d after onset (<em>t</em> = 9.925, <em>P</em> = 0.015). The statin group also had better 3-month outcome ( <em>χ²</em> = 4.762, <em>P</em> = 0.029). After using stepwise Logistic regression analysis, only National Institute of Health Stroke Scale (NIHSS) score on admission (<em>OR</em> = 1.383, 95%CI: 1.062-1.800; <em>P</em> = 0.028) and hs-CRP in the acute phase (<em>OR</em> = 1.472, 95%CI: 0.500-4.370; <em>P</em> = 0.001) were significantly and independently predictive for 3-month outcome. This study indicates that statin therapy reduces hs-CRP level in the acute phase and can predict the 3-month clinical outcome of ischemic stroke.</p><p> </p><p>doi: 10.3969/j.issn.1672-6731.2014.08.013</p>